Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Courtney Zeni"'
Autor:
Rashmi Patel, Carole Dembek, Yida Won, Aditi Kadakia, Xueyan Huang, Courtney Zeni, Andrei Pikalov
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Objectives Negative symptoms in schizophrenia are associated with significant illness burden. We sought to investigate clinical outcomes for patients with schizophrenia who present with predominant negative symptoms (PNS) vs without PNS.Design Retros
Externí odkaz:
https://doaj.org/article/b031ce8b1ace4d42a39b2d969e3b5df3
Autor:
Anne Rivelli, Veronica Fitzpatrick, Michael Nelson, Kimberly Laubmeier, Courtney Zeni, Srikrishna Mylavarapu
Publikováno v:
Schizophrenia, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Schizophrenia is often characterized by recurring relapses, which are associated with a substantial clinical and economic burden. Early identification of individuals at the highest risk for relapse in real-world treatment settings could help
Externí odkaz:
https://doaj.org/article/6fb041e8ade3456396c0724aeefa8d66
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 24, p 13185 (2021)
Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target for neuropsychiatric disorders due to its ability to modulate monoaminergic and glutamatergic neurotransmission. In particular, agonist compounds have generated i
Externí odkaz:
https://doaj.org/article/24a2a645c47f4a17ae96659ce4bf3218
Publikováno v:
Current Medical Research and Opinion. 39:467-471
Schizophrenia is a chronic, heterogeneous, severe psychiatric disorder characterized by a spectrum of symptomology and is associated with substantial morbidity and mortality. For the last 70 years, available treatments have shared blockade of dopamin
Publikováno v:
Clinical Drug Investigation. 42:1113-1121
Publikováno v:
European Archives of Psychiatry and Clinical Neuroscience.
Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development for the treatment of schizophrenia. Ulotaront was discovered through a unique, target-agnostic approach optimized to identify drug candidates lacking D2
Autor:
Rashmi Patel, Darshan Mehta, Aditi Kadakia, Yida Won, Carole Dembek, Gwilym Williams, Xueyan Huang, Courtney Zeni, Andrei Pikalov
Publikováno v:
CNS Spectrums. 28:222-223
IntroductionCurrently approved treatments for schizophrenia (antipsychotics) have demonstrated effectiveness for treating positive symptoms; however, these agents are largely ineffective in treating other domains. Negative symptoms, including avoliti
Publikováno v:
CNS Spectrums. 28:221-221
IntroductionTrace amine-associated receptors (TAARs) are a family of G-protein-coupled receptors (GPCRs) first identified in 2001. TAAR1 has emerged as a promising therapeutic target due to its ability to modulate monoaminergic and glutamatergic neur
Autor:
Nina Dedic, Philip G. Jones, Eva Hajos-Korcsok, Colleen Synan, Serena Wu, Christoph Anacker, Steve P. Vickers, Jacob Hecksher-Sørensen, Courtney Zeni, Snezana Milanovic, Seth C. Hopkins, Linda J. Bristow, Kenneth S. Koblan
Publikováno v:
CNS Spectrums. 28:259-259
IntroductionPreclinical evidence has identified the trace amine-associated receptor 1 (TAAR1) as a novel regulator of metabolic control. Ulotaront is a TAAR1 and 5-HT1A agonist currently in Phase 3 clinical trials for the treatment of schizophrenia.
Publikováno v:
CNS Spectrums. 28:221-221
IntroductionUlotaront is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity that has received FDA Breakthrough Therapy Designation for the treatment of schizophrenia. Here we summarize ongoing clinical research